Nisa Investment Advisors
ABCL icon

Nisa Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Nisa Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-610
Closed -$3.07K – 2962
2025
Q3 		$3.07K Hold
610
– – ﹤0.01% 2532
2025
Q2 		$2.09K Hold
610
– – ﹤0.01% 2599
2025
Q1 		$1.36K Hold
610
– – ﹤0.01% 2558
2024
Q4 		$1.79K Hold
610
– – ﹤0.01% 2522
2024
Q3 		$1.59K Hold
610
– – ﹤0.01% 2459
2024
Q2 		$1.81K Hold
610
– – ﹤0.01% 2388
2024
Q1 		$2.76K Hold
610
– – ﹤0.01% 2185
2023
Q4 		$3.48K Sell
610
-60
-9% -$278 ﹤0.01% 2149
2023
Q3 		$3.08K Hold
670
– – ﹤0.01% 2319
2023
Q2 		$4.33K Sell
670
-1,250
-65% -$8.53K ﹤0.01% 2332
2023
Q1 		$14K Sell
1,920
-6,185
-76% -$56.2K ﹤0.01% 2089
2022
Q4 		$82K Hold
8,105
– – ﹤0.01% 1618
2022
Q3 		$96K Buy
8,105
+145
+2% +$1.59K ﹤0.01% 1519
2022
Q2 		$85K Buy
+7,960
New +$67.4K ﹤0.01% 1550

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nisa Investment Advisors's ABCL Position: Q4 2025 in Review

Nisa Investment Advisors sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 610 shares — an estimated $3.07K sold.

Nisa Investment Advisors first reported a position in ABCL in Q2 2022 and held it in 14 quarters. The position peaked at $96K in Q3 2022. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Nisa Investment Advisors reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 610 AbCellera Biologics shares in Q4 2025, an estimated $3.07K.
  • Nisa Investment Advisors first reported a position in AbCellera Biologics in Q2 2022 and held it in 14 quarters.
  • Nisa Investment Advisors's AbCellera Biologics position peaked at $96K in Q3 2022.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.